Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 12/20 | 0.35 |
| ▸ | HTR2C | P28335 | 12/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12439352 | 0.89 | HTR2A (0.44) | SLC6A2HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL8319596 | 0.89 | HTR2A (0.44) | SLC6A2HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL799374 | 0.89 | HTR2A (0.44) | SLC6A2HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL2743279 | 0.80 | HTR2A (0.33) | SLC6A2HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL13860754 | 0.77 | SIGMAR1 (0.38) | SIGMAR1HTR2AHTR2CL3MBTL1 | |
| SCHEMBL799397 | 0.76 | HTR2A (0.54) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL24721280 | 0.76 | SIGMAR1 (0.42) | SIGMAR1HTR2AL3MBTL1 | |
| SCHEMBL690716 | 0.76 | SIGMAR1 (0.42) | SIGMAR1HTR2AL3MBTL1 | |
| SCHEMBL13935740 | 0.76 | SIGMAR1 (0.42) | SIGMAR1HTR2AL3MBTL1 | |
| SCHEMBL15867020 | 0.75 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1LMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | SIGMAR1 2789/4885SLC6A2 3739/4885HTR2A 2842/4885 |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | SIGMAR1 2357/4885SLC6A2 3761/4885HTR2A 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.